 FSD Pharma Inc. Nasdaq: HUGE CSE: HUGE.CN FRA: 0K9A FSD Pharma or the Company today announced favorable topline results from its Phase 1 randomized, double-blind, placebo-controlled study of ultramicronized palmitoylethanolamide PEA, or FSD201. This single-site study was conducted at the Alfred Hospital, part of the Alfred Health group of hospitals serving the state of Victoria in Australia and enrolled 48 healthy adult men and women. 